Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated	12 Months Ended
	Jul. 31, 2023
Broad Atlantic Associates, LLC [Member]
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]
Country of Incorporation	United States – Delaware
Percentage Owned	100.00%
IDT R.E. Holdings Ltd. [Member]
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]
Country of Incorporation	Israel
Percentage Owned	100.00%
Rafael Holdings Realty, Inc. [Member]
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]
Country of Incorporation	United States – Delaware
Percentage Owned	100.00%
Barer Institute, Inc. [Member]
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]
Country of Incorporation	United States – Delaware
Percentage Owned	100.00%	[1]
The Barer Institute, LLC [Member]
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]
Country of Incorporation	United States – Delaware
Percentage Owned	100.00%	[1]
Hillview Avenue Realty, JV [Member]
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]
Country of Incorporation	United States – Delaware
Percentage Owned	100.00%
Hillview Avenue Realty, LLC [Member]
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]
Country of Incorporation	United States – Delaware
Percentage Owned	100.00%
Rafael Medical Devices, Inc. [Member]
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]
Country of Incorporation	United States – Delaware
Percentage Owned	100.00%
Levco Pharmaceuticals Ltd. [Member]
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]
Country of Incorporation	Israel
Percentage Owned	95.00%	[2]
Farber Partners, LLC [Member]
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]
Country of Incorporation	United States – Delaware
Percentage Owned	93.00%
Pharma Holdings, LLC [Member]
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]
Country of Incorporation	United States – Delaware
Percentage Owned	90.00%
LipoMedix Pharmaceuticals Ltd. [Member]
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]
Country of Incorporation	Israel
Percentage Owned	95.00%	[3]
Altira Capital & Consulting, LLC [Member]
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]
Country of Incorporation	United States – Delaware
Percentage Owned	67.00%
CS Pharma Holdings, LLC [Member]
Description of Business (Details) - Schedule of All Majority-Owned Subsidiaries are Consolidated [Line Items]
Country of Incorporation	United States – Delaware
Percentage Owned	45.00%	[4]

[1] In November 2022, the Company resolved to curtail its early-stage development efforts, including pre-clinical research at Barer. The decision was taken to reduce spending as the Company focuses on exploring strategic opportunities.

[2] During Fiscal 2022, the Company discontinued further material investment in Levco.

[3] On February 9, 2023, the Company increased its ownership interest in LipoMedix Pharmaceuticals Ltd. an additional 11% from 84% to 95%.

[4] 50% of CS Pharma Holdings, LLC is owned by Pharma Holdings, LLC. We have a 90% ownership in Pharma Holdings, LLC and, therefore, an effective 45% interest in CS Pharma Holdings, LLC. The Company, along with CS Pharma and Pharma Holdings, collectively own securities representing 51% of the outstanding capital stock of Cornerstone Pharmaceuticals and 42% of the capital stock on a fully diluted basis (excluding the remainder of the Warrant). Refer to Note 4 for further details.